Kodiak Sciences Inc.
Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.
KOD | NDAQ
Overview
Corporate Details
- ISIN(s):
- US50015M1099
- LEI:
- Country:
- United States of America
- Address:
- 1200 PAGE MILL RD, 94304 PALO ALTO
- Website:
- https://kodiak.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for high-prevalence retinal diseases. The company's mission is to prevent and treat leading causes of blindness, such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Its core technology is the proprietary Antibody Biopolymer Conjugate (ABC) platform, engineered to create novel biologics with high durability and efficacy. Kodiak's late-stage pipeline includes several product candidates, such as tarcocimab tedromer, KSI-501, and KSI-101, which target a broad spectrum of retinal vascular and inflammatory conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Kodiak Sciences Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kodiak Sciences Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kodiak Sciences Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
